ISPECIMEN INC (ISPC)

US45032V1089 - Common Stock

4.2  -0.15 (-3.45%)

After market: 4.26 +0.06 (+1.43%)

Fundamental Rating

3

ISPC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 37 industry peers in the Health Care Technology industry. While ISPC seems to be doing ok healthwise, there are quite some concerns on its profitability. ISPC is valied quite expensively at the moment, while it does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

ISPC had negative earnings in the past year.
ISPC had a negative operating cash flow in the past year.
ISPC had negative earnings in each of the past 5 years.
ISPC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of ISPC (-85.65%) is worse than 86.11% of its industry peers.
ISPC has a Return On Equity of -167.41%. This is amonst the worse of the industry: ISPC underperforms 80.56% of its industry peers.
Industry RankSector Rank
ROA -85.65%
ROE -167.41%
ROIC N/A
ROA(3y)-45.63%
ROA(5y)-64.82%
ROE(3y)-64.83%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of ISPC (50.12%) is worse than 61.11% of its industry peers.
In the last couple of years the Gross Margin of ISPC has grown nicely.
ISPC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.92%
GM growth 5Y2.16%

5

2. Health

2.1 Basic Checks

ISPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ISPC has less shares outstanding
Compared to 5 years ago, ISPC has less shares outstanding
ISPC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -9.17, we must say that ISPC is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -9.17, ISPC is not doing good in the industry: 88.89% of the companies in the same industry are doing better.
There is no outstanding debt for ISPC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.17
ROIC/WACCN/A
WACC9.07%

2.3 Liquidity

A Current Ratio of 0.90 indicates that ISPC may have some problems paying its short term obligations.
ISPC has a worse Current ratio (0.90) than 75.00% of its industry peers.
A Quick Ratio of 0.90 indicates that ISPC may have some problems paying its short term obligations.
ISPC's Quick ratio of 0.90 is on the low side compared to the rest of the industry. ISPC is outperformed by 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.9

4

3. Growth

3.1 Past

ISPC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.26%, which is quite good.
Looking at the last year, ISPC shows a decrease in Revenue. The Revenue has decreased by -4.54% in the last year.
Measured over the past years, ISPC shows a quite strong growth in Revenue. The Revenue has been growing by 17.73% on average per year.
EPS 1Y (TTM)17.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.35%
Revenue 1Y (TTM)-4.54%
Revenue growth 3Y6.67%
Revenue growth 5Y17.73%
Sales Q2Q%-4.24%

3.2 Future

ISPC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.24% yearly.
Based on estimates for the next years, ISPC will show a quite strong growth in Revenue. The Revenue will grow by 9.14% on average per year.
EPS Next Y96.29%
EPS Next 2Y40.24%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year6.58%
Revenue Next 2Y9.14%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ISPC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ISPC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ISPC's earnings are expected to grow with 40.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.24%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

ISPC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ISPECIMEN INC

NASDAQ:ISPC (11/15/2024, 8:19:21 PM)

After market: 4.26 +0.06 (+1.43%)

4.2

-0.15 (-3.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.03M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -85.65%
ROE -167.41%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 50.12%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.9
Quick Ratio 0.9
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)17.26%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y96.29%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-4.54%
Revenue growth 3Y6.67%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y